Lonergan Peter E, Porten Sima P
Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA.
Transl Androl Urol. 2020 Aug;9(4):1891-1896. doi: 10.21037/tau.2020.03.47.
Upper tract urothelial carcinoma (UTUC) is a relatively uncommon and poorly investigated malignancy, however, bladder recurrence after radical nephroureterectomy (RNU) is a frequent event. In this review, we summarize the current knowledge on risk prediction of bladder tumor recurrence after RNU, including surgical strategies and adjuvant intravesical treatments to reduce the risk of recurrence. Finally, we outline some of the more recent advances in genomics that will likely lead to new prognostic markers and risk stratification tools that may refine UTUC treatment in the future.
上尿路尿路上皮癌（UTUC）是一种相对罕见且研究较少的恶性肿瘤，然而，根治性肾输尿管切除术（RNU）后膀胱复发是常见事件。在本综述中，我们总结了目前关于RNU后膀胱肿瘤复发风险预测的知识，包括手术策略和辅助膀胱内治疗以降低复发风险。最后，我们概述了基因组学方面的一些最新进展，这些进展可能会带来新的预后标志物和风险分层工具，有望在未来优化UTUC的治疗。
